Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-leukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models.
Kannan S, Li Y, Baran N, Yang X, Ghotbaldini S, Tatarata QZ, Yoshimura S, Li Z, Hsiao YC, Balachander SB, Andersen CL, Cidado J, Yu J, Jain N, Yang JJ, Konopleva MY. Kannan S, et al. Among authors: balachander sb. Blood Adv. 2024 Nov 19:bloodadvances.2024013423. doi: 10.1182/bloodadvances.2024013423. Online ahead of print. Blood Adv. 2024. PMID: 39561378
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes.
Vasalou C, Ferguson D, Li W, Muse V, Gibbons FD, Sonzini S, Zhang G, Pop-Damkov P, Gangl E, Balachander SB, Wen S, Schuller AG, Puri S, Mazza M, Ashford M, Fretland AJ, McGinnity DF, Jones RDO. Vasalou C, et al. Among authors: balachander sb. Mol Pharm. 2022 Jan 3;19(1):172-187. doi: 10.1021/acs.molpharmaceut.1c00715. Epub 2021 Dec 10. Mol Pharm. 2022. PMID: 34890209
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.
Arulananda S, O'Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, Leong T, Mariadason JM, Cebon J, Balachander SB, Cidado JR, Lee EF, John T, Fairlie WD. Arulananda S, et al. Among authors: balachander sb. Cell Death Discov. 2021 May 28;7(1):122. doi: 10.1038/s41420-021-00505-0. Cell Death Discov. 2021. PMID: 34050131 Free PMC article.
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy.
Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, Parker J, Giannis M, Hill KJ, Gibbons FD, Hennessy EJ, Kemmitt P, Harmer AR, Gales S, Purbrick S, Redmond S, Skinner M, Graham L, Secrist JP, Schuller AG, Wen S, Adam A, Reimer C, Cidado J, Wild M, Gangl E, Fawell SE, Saeh J, Davies BR, Owen DJ, Ashford MB. Patterson CM, et al. Among authors: balachander sb. Commun Biol. 2021 Jan 25;4(1):112. doi: 10.1038/s42003-020-01631-8. Commun Biol. 2021. PMID: 33495510 Free PMC article.
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P, Macintyre T, Wen S, Lawson D, Burke K, Lubinski T, Tyner JW, Kurtz SE, McWeeney SK, Varnes J, Diebold RB, Gero T, Ioannidis S, Hennessy EJ, McCoull W, Saeh JC, Tabatabai A, Tavana O, Su N, Schuller A, Garnett MJ, Jaaks P, Coker EA, Gregory GP, Newbold A, Johnstone RW, Gangl E, Wild M, Zinda M, Secrist JP, Davies BR, Fawell SE, Gibbons FD. Balachander SB, et al. Clin Cancer Res. 2020 Dec 15;26(24):6535-6549. doi: 10.1158/1078-0432.CCR-20-0863. Epub 2020 Sep 28. Clin Cancer Res. 2020. PMID: 32988967